Key updates on Down syndrome community access to new Alzheimer’s drugs
Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC is working on many levels
July 7, 2023
Five takeaways for the Down syndrome community: Updates on accessing the new Alzheimer’s drugsLuMind IDSC is working on many levels
LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease July 7, 2023 In a
Last week the FDA announced a full approval of a new drug called Leqembi to treat Alzheimer’s Disease. The approval
Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from accessing new therapies for Alzheimer’s
An international group of experts convened to determine prescribing criteria equivalences that would be inclusionary of adults with Down syndrome.
In April, leaders from LuMind IDSC joined with 350 self-advocates, caregivers, and professionals to meet with federal legislators in a
Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves their anti-amyloid drug, donanemab, significantly
At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve Stimulator for children with Down
“Alzheimer’s meds are here. But for the Down syndrome community, it’s still the 1980s” by Annalee Armstrong, Fierce Biotech An
2/22/2023 (Burlington, MA) – Today the LuMind IDSC Foundation, a leading national Down syndrome research organization, announced a new collaboration